BRPI0813000A2 - Composições terapêuticas e uso das mesmas - Google Patents

Composições terapêuticas e uso das mesmas

Info

Publication number
BRPI0813000A2
BRPI0813000A2 BRPI0813000-0A2A BRPI0813000A BRPI0813000A2 BR PI0813000 A2 BRPI0813000 A2 BR PI0813000A2 BR PI0813000 A BRPI0813000 A BR PI0813000A BR PI0813000 A2 BRPI0813000 A2 BR PI0813000A2
Authority
BR
Brazil
Prior art keywords
therapeutic compositions
therapeutic
compositions
Prior art date
Application number
BRPI0813000-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Anita A Mathias
Srinivasan Ramanathan
Brian P Kearney
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BRPI0813000A2 publication Critical patent/BRPI0813000A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0813000-0A2A 2007-06-29 2008-06-26 Composições terapêuticas e uso das mesmas BRPI0813000A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94730607P 2007-06-29 2007-06-29
US4092008P 2008-03-31 2008-03-31
PCT/US2008/068339 WO2009006199A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
BRPI0813000A2 true BRPI0813000A2 (pt) 2014-12-23

Family

ID=39831893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813000-0A2A BRPI0813000A2 (pt) 2007-06-29 2008-06-26 Composições terapêuticas e uso das mesmas

Country Status (19)

Country Link
US (4) US20100331331A1 (OSRAM)
EP (1) EP2167088A1 (OSRAM)
JP (3) JP5547066B2 (OSRAM)
KR (1) KR20100040892A (OSRAM)
CN (2) CN101686972B (OSRAM)
AP (1) AP2965A (OSRAM)
AR (1) AR067183A1 (OSRAM)
AU (1) AU2008270630B2 (OSRAM)
BR (1) BRPI0813000A2 (OSRAM)
CA (1) CA2692101A1 (OSRAM)
CO (1) CO6251237A2 (OSRAM)
EA (1) EA200971093A1 (OSRAM)
EC (1) ECSP109897A (OSRAM)
IL (1) IL202744A0 (OSRAM)
MX (1) MX2009013829A (OSRAM)
NZ (1) NZ582086A (OSRAM)
SG (1) SG182229A1 (OSRAM)
TW (1) TW200914011A (OSRAM)
WO (1) WO2009006199A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018544B1 (ru) * 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
AR061838A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
CN105503721A (zh) 2006-09-12 2016-04-20 吉里德科学公司 制备整合酶抑制剂的方法和中间体
EP2118082B1 (en) * 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2692101A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
AU2008270634B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
AP3089A (en) 2008-05-02 2015-01-31 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US20130203759A1 (en) * 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
US20130274254A1 (en) * 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
WO2015120057A1 (en) * 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (OSRAM) 2014-06-20 2018-06-23
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6544540B2 (en) * 1998-07-29 2003-04-08 Syngenta Limited Base-triggered release microcapsules
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
EA018544B1 (ru) * 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AR061838A1 (es) * 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
CN105503721A (zh) * 2006-09-12 2016-04-20 吉里德科学公司 制备整合酶抑制剂的方法和中间体
AU2008270634B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
CA2692101A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
AP3089A (en) * 2008-05-02 2015-01-31 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
ECSP109897A (es) 2010-03-31
AP2009005074A0 (en) 2009-12-31
KR20100040892A (ko) 2010-04-21
CN101686972B (zh) 2013-08-14
JP2010532372A (ja) 2010-10-07
CA2692101A1 (en) 2009-01-08
CN101686972A (zh) 2010-03-31
CO6251237A2 (es) 2011-02-21
TW200914011A (en) 2009-04-01
SG182229A1 (en) 2012-07-30
MX2009013829A (es) 2010-03-10
JP5769763B2 (ja) 2015-08-26
US20090093467A1 (en) 2009-04-09
EP2167088A1 (en) 2010-03-31
EA200971093A1 (ru) 2010-08-30
US20100331331A1 (en) 2010-12-30
AR067183A1 (es) 2009-09-30
AP2965A (en) 2014-09-30
CN103480000A (zh) 2014-01-01
US20170136001A1 (en) 2017-05-18
WO2009006199A1 (en) 2009-01-08
IL202744A0 (en) 2010-06-30
US20140343063A1 (en) 2014-11-20
AU2008270630B2 (en) 2014-01-16
JP2015143278A (ja) 2015-08-06
JP5547066B2 (ja) 2014-07-09
JP2013199495A (ja) 2013-10-03
AU2008270630A1 (en) 2009-01-08
NZ582086A (en) 2012-07-27

Similar Documents

Publication Publication Date Title
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
CY2019010I1 (el) Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0811871A2 (pt) Composições agroquímicas ácidas bioativas e uso das mesmas
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BRPI0818766A2 (pt) N-fenil-pirrolidinilmetilpirrolidinamidas substituídas e uso terapêutico das mesmas
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
BR112013014231A2 (pt) composição de higiene pessoal e uso da composição de higiene pessoal
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
PL2059223T3 (pl) Kompozycja do pielęgnacji skóry
PT2124638T (pt) Composição de aperfeiçoamento de desempenho e utilização da mesma
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BR112012003445A2 (pt) aparelho dental sem o uso das maos para limpeza dos dentes
ES2411907T8 (es) Uso terapéutico de anticuerpos antirreceptor TWEAK
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0914488A2 (pt) "composições de limpeza incluindo siloxanos de sorbitano modificados e uso das mesmas"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.